News | June 02, 2015

Proton Therapy Has Fewer Side Effects in Esophageal Cancer Patients

Study discovers significant differences from current radiation therapies

June 2, 2015 - New research has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies. The research was conducted by scientists at the University of Maryland School of Medicine.

Michael Choung, M.D., assistant professor of radiation oncology at the university, worked with colleagues at the Mayo Clinic in Rochester, Minnesota, and the MD Anderson Cancer Center in Dallas to compare two kinds of X-ray radiation with proton therapy - a precise approach that targets tumors while minimizing harm to surrounding tissues.

The researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite. The results were presented at the annual conference of the Particle Therapy Cooperative Group, held in San Diego.

"This evidence underscores the precision of proton therapy and how it can really make a difference in cancer patients' lives," said Chuong.

Patients with esophageal cancer can suffer a range of side effects, including nausea, fatigue, lack of appetite, blood abnormalities, and lung and heart problems. Proton therapy did not make a difference in all of these side effects, but had significant effects on several.

The results have particular relevance for the University of Maryland School of Medicine, as this fall the school will open the Maryland Proton Treatment Center (MPTC). The center will provide one of the newest and most highly precise forms of radiation therapy available, pencil beam scanning (PBS), which targets tumors while significantly decreasing radiation doses to healthy tissue. This technique can precisely direct radiation to the most difficult-to-reach tumors.

Proton therapy is just one of several new methods for treating cancer. Others include:

  • Selective internal radiation therapy, a precision modality for treating patients with particularly difficult-to-remove tumors involving the liver such as those from colorectal cancers;
  • Gammapod, a new high-precision, noninvasive method of treating early-stage breast cancer; and
  • Thermal therapies, the use of "heat" in treating a broad spectrum of malignancies.

 

The treatment works well for many kinds of tumors, including those found in the brain, esophagus, lung, head and neck, prostate, liver, spinal cord and gastrointestinal system. It is also an important option for children with cancer and is expected to become an important option for some types of breast cancer. While most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.

Located at the University of Maryland BioPark, the 110,000 square-foot, $200 million center is expected to treat about 2,000 patients a year.

For more information: www.medschool.umaryland.edu

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
Overlay Init